# Cognitive outcome in relation to cerebrospinal fluid markers of neuronal and glial cell damage: A prospective study of tick-borne encephalitis.

- **DOI:** [10.1016/j.ttbdis.2026.102673](https://doi.org/10.1016/j.ttbdis.2026.102673)
- **Rating:** Sound (3.2 out of 5)
- **Verdict:** Acute CSF GFAP emerges as a candidate marker of later cognitive impairment after tick-borne encephalitis, but the evidence remains exploratory.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-19
- **Evaluation page:** https://www.nabu.science/paper/10.1016%2Fj.ttbdis.2026.102673

## Key claims

1. CSF GFAP showed the strongest association with long-term cognitive outcome and may reflect astrocytic activation related to persistent cognitive impairment.
   - Support: Tentative
   - Type: Primary finding
   - Basis: exploratory observational evidence without a formal comparative test establishing GFAP superiority
   - Location: Abstract, Conclusion
2. only CSF GFAP remained a significant predictor of CI after adjustment for age, education, and time-to-testing.
   - Support: Tentative
   - Type: Secondary
   - Basis: small exploratory cohort with correlation-selected biomarkers and a marginal adjusted result among uncorrected tests
   - Location: Abstract, Results; Table 4
3. In ROC analysis, CSF GFAP displayed high specificity (83%) but low sensitivity (35%).
   - Support: Tentative
   - Type: Secondary
   - Basis: predictive performance estimated in a small exploratory cohort without independent validation
   - Location: Abstract, Results
4. CI was common, particularly affecting verbal working memory and processing speed.
   - Support: Supported
   - Type: Secondary
   - Basis: descriptive cohort findings under a sensitive one-test impairment definition without matched controls
   - Location: Abstract, Results; Fig. 1

## Strengths

- **Prospective sampling precedes later cognitive assessment** Acute CSF and serum sampling precedes follow-up cognitive testing, providing the temporal structure needed to study prognostic associations. Assays were conducted in a single batch with reported intra-assay variation below 10%.
  - Dimension: methodological rigour
  - Location: Methods §§2.1–2.3
- **New cognitive outcome link for GFAP** The study extends earlier TBE severity-biomarker work by examining later cognitive outcomes. CSF GFAP retains a nominally significant association after adjustment for age, education, and time-to-testing.
  - Dimension: contribution
  - Location: Introduction; Table 4; Discussion
- **Limitations connected to cautious clinical interpretation** The discussion addresses test-version differences, the sensitive impairment definition, biomarker timing, and multiple exploratory analyses. It also distinguishes a possible risk marker from a rule-out test given the low sensitivity.
  - Dimension: positioning
  - Location: Discussion, limitations and predictive-utility paragraphs

## Limitations

- **Multiple testing leaves the central signal fragile** Numerous biomarker–domain correlations and subsequent models are evaluated without multiplicity control. The only significant adjusted association has p=.04 and a confidence interval of 1.05–4.07.
  - Dimension: methodological rigour
  - Location: Methods §2.7; Tables 3–4
- **Sensitive impairment definition lacks robustness checks** Impairment on any one completed test defines the binary outcome, without a matched control group or analyses using more conservative definitions. This limits interpretation of both prevalence and the biomarker association.
  - Dimension: methodological rigour
  - Location: Methods §§2.3–2.4; Discussion, limitations
- **Headline superiority exceeds the reported comparison** The Abstract describes GFAP as having the strongest association, but no formal head-to-head comparison establishes that it outperforms the other biomarkers. Being the only adjusted result below p=.05 does not establish superiority.
  - Dimension: reporting
  - Location: Abstract, Conclusion; Table 4

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - CSF GFAP showed the strongest association with long-term cognitive outcome and may reflect astrocytic activation related to persistent cognitive impairment: "CSF and serum samples were collected within 14 days of symptom onset" (Abstract, Methods) vs "availability of paired CSF and serum samples within 14 days of" (Section 2.1 Participants). The Abstract anchors the 14-day window to symptom onset, whereas Methods §2.1 and Table 1 anchor sampling to hospitalization or admission, leaving onset-to-sampling time unresolved. → Effect on result unclear
  - CI was common, particularly affecting verbal working memory and processing speed: "Cognitive impairment at follow-up 92 59 62" (Table 1, Cognitive impairment at follow-up row). 59 divided by 92 multiplied by 100 equals 64.13%, which rounds to 64%, not the reported 62%. → Conclusion holds
- **Reporting and transparency:** Noted. Ethics approval, consent, competing interests, and consent-based restrictions on data sharing are declared. The pooled-cohort discussion reports a country difference in severity without presenting the underlying analysis.
  - Conflict of interest: declared · Ethics approval: declared · Data availability: not stated
- **Reference integrity:** Clean
  - 32 references in manuscript
  - 29 of 30 checkable references found in an index
  - 2 have no canonical index record — counted, but not index-checkable
  - 1 reference confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-19
